The chief medical officer at Athira Pharma talked about an exploratory phase 2 trial that showcased the correlation between biomarkers for Alzheimer disease hallmarks and neuroinflammation. [WATCH TIME: 5 minutes]
Hans J. Moebius, MD, PhD
Advertisement
The chief medical officer at Athira Pharma.
Articles by Hans J. Moebius, MD, PhD
At the 2023 AAN Annual Meeting, the chief medical officer at Athira Pharma spoke about findings from a phase 2 trial in which various biomarkers related to neurodegeneration showed significant improvements. [WATCH TIME: 4 minutes]
Advertisement
Latest Updated Articles
Neuroprotection and Inflammation Reduction, Improvement in Biomarkers From ACT-AD Study: Hans J. Moebius, MD, PhDPublished: May 14th 2023 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
NeurologyLive® Friday 5 — November 7, 2025
2
Supplemental New Drug Application Submitted for AXS-05 as Treatment for Alzheimer Disease Agitation
3
Preliminary Phase 2 Data Support Therapeutic Development of Synaptic Regenerative Drug SPG302 in ALS
4
ALS Qualitative Study Highlights Complexities of Decision-Making Process for Medical Aid in Dying (MAID)
5
